Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Red Blood Cell Transfusions for Sickle Cell Disease
source: St. Jude Children’s Research Hospital
year: N/A
summary/abstract:This type of procedure involves the transfer of red blood cells from one (1) person to another. Red blood cells are obtained when a person donates blood. The red cells are separated from the other parts of blood. These red blood cells are collected in a bag, stored in a refrigerator, and then given to another person through a vein. Donated blood cells are carefully tested for infections and closely matched to the recipient to prevent reactions.
Normal red blood cells carry oxygen throughout the body. The red blood cells of people with sickle cell disease do not deliver oxygen as well as normal red blood cells do.
In addition, these cells may change into a sickle shape, which blocks the flow of blood through the vessels. When a person with sickle cell disease has certain complications (health problems) from the disease, transfusing normal red blood cells may help deliver oxygen to the body and unblock blood vessels.
read more
Related Content
-
Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occ...Hydroxyurea (HU) is approved in EU and U...
-
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Diseasehttps://www.youtube.com/watch?v=CWTW5pDP...
-
Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
-
The influence of the age of adults with sickle cell disease on the uptake, utilization and efficacy of HydroxyureaDespite the efficacy of Hydroxyurea (HU)...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
Advances in the Treatment of Sickle Cell Disease: L-Glutamine, Crizanlizumab & Gene Therapyhttps://www.youtube.com/watch?v=wkm4axJ3...
-
Crizanlizumab lowers pain crises in at-risk sickle cell patients, ad-hoc trial data showNovartis’ investigational th...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.